Company Overview and News
A strong day for Indian markets supported by short coverings as the S&P BSE Sensex rallied over 300 points and the Nifty50 managed to close above 50-days moving average and 100-DEMA on Thursday.
New Delhi : The National Company Law Appellate Tribunal on Thursday admitted an appeal moved by ICICI Bank, Axis Bank and others challenging an order passed by the Allahabad bench of the National Company Law Tribunal directing Jaiprakash Associates to return over 700 acres of land to its subsidiary Jaypee Infratech.
Mumbai: The BSE Sensex rose over 187 points in early trade today, extending yesterday’s rally on robust buying in IT, energy and banking stocks amid unabated purchases by domestic institutional investors. Asian shares were mixed after US President Donald Trump cancelled a planned meeting with North Korean leader Kim Jong Un.
Benchmark indices rose, driven by IT stocks, such as, Infosys and TCS on the back of a weak rupee. The IT index has gained 18 percent so far this year. The rupee has weakened by more than 7 percent so far this year, as surging crude oil prices weigh on India, the world’s third-largest importer, raising fears that soaring costs could drive up inflation and widen the trade deficit.
New Delhi: The National Company Law Appellate Tribunal (NCLAT) on Thursday admitted an appeal moved by ICICI Bank Ltd and other lenders challenging an order passed by National Company Law Tribunal’s (NCLT) Allahabad bench directing Jaiprakash Associates Ltd (JAL) to return 759 acres of land to its unit Jaypee Infratech Ltd (JIL).
The market managed to recover all its previous session's losses on Thursday, led by short covering in beaten down stocks. Dovish Federal Reserve minutes, correction in crude oil prices and the recovery in rupee also aided sentiment.
The S&P BSE Sensex snapped its 5-day losing streak and closed in positive making a small bullish candle on the daily candlestick charts on Tuesday. The Nifty50 also held on to its crucial support level placed at 10,500 levels, but closed below its 100-days moving average placed around 10,540.
New Delhi:The Delhi high court on Monday directed Axis Bank to renew all pending bank guarantees with respect to Reliance Communications Ltd (RCom), whether expired or yet to expire, as an interim measure.
Buzzing: Shares of Dilip Buildcon fell 5.6 percent intraday as company's promoters pledged their shares with RBL Bank.
Buzzing: Shares of Indoco Remedies rose over 4 percent as USFDA has successfully completed the inspection at its manufacturing facilities.
Pre-Opening Rate: Indostar Capital Finance share price settled at Rs 600 on the National Stock Exchange, up 4.9 percent compared to issue price of Rs 572.
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
Benchmark indices extended losses for fourth consecutive session on Thursday, weighed by banking & financials, metals, infra and oil stocks.
The rise in bad loans and subdued corporate demand is driving banks to explore new business models, cross-sell products with more retail-oriented segments for growth. They are stepping up credit monitoring standards to lend to good quality customers.
Fund Raising: Infrastructure firm NCC said its board will meet next week to consider raising funds through issuance of equity shares or warrants to promoters on preferential basis.
22h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
22h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...